Stock Report

Download full stock data and analysis for free Last Updated: 08-May-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Alimera Sciences Inc. (ALIM)

Stock Card factsheet share-fund-plan-icon

$5.54

$0.00 (0.00%)

As on 18-Sep-2024 09:30EDT

Market cap

info icon

$301 Mln

Revenue (TTM)

info icon

$100 Mln

P/E Ratio

info icon

5.3

P/B Ratio

info icon

7.8

Div. Yield

info icon

0 %

Alimera Sciences (ALIM) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio
NASDAQ
NASDAQ

Stock Range

Today’s Range

Low: 5.54 High: 5.54

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -0.3 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    26.31

  • EV/EBITDAEV/EBITDA information

    31.7

  • Debt to EquityDebt to Equity information

    1.8

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-0.4

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    54,384,200

10 Years Aggregate

CFO

$-153.00 Mln

EBITDA

$-117.19 Mln

Net Profit

$-196.51 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Alimera Sciences (ALIM)
28.2 -0.7 70.5 66.9 4.5 -2.1 -22.9
BSE Sensex*
-8.7 3.6 -7.5 -4.2 8.2 9.5 11.9
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 18-Sep-2024  |  *As on 08-May-2026  |  #As on 26-Oct-2023
Company
2023
2022
2021
2020
2019
2018
2017
Alimera Sciences (ALIM)
59.4 -47.2 21.6 -44.3 -29.6 -45.8 23.1
S&P Small-Cap 600
13.9 -17.4 25.3 9.6 20.9 -9.7 11.7
BSE Sensex
18.7 4.4 22.0 15.8 14.4 5.9 27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Alimera Sciences (ALIM)

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone...  acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.  Read more

  • CEO & Director

    Mr. Richard S. Eiswirth Jr.

  • CEO & Director

    Mr. Richard S. Eiswirth Jr.

  • Headquarters

    Alpharetta, GA

  • Website

    https://alimerasciences.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Alimera Sciences (ALIM)

The share price of Alimera Sciences Inc (ALIM) is $5.54 (NASDAQ) as of 18-Sep-2024 09:30 EDT. Alimera Sciences Inc (ALIM) has given a return of 4.46% in the last 3 years.

The P/E ratio of Alimera Sciences Inc (ALIM) is 5.28 times as on 18-Sep-2024, a 80 discount to its peers’ median range of 26.31 times.
The P/B ratio of Alimera Sciences Inc (ALIM) is 7.77 times as on 18-Sep-2024, a 33 premium to its peers’ median range of 5.84 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2023
-5.58
2.43
2022
-1.05
-0.91
2021
-8.21
-13.79
2020
-3.95
-2.64
2019
-3.63
-8.53

The 52-week high and low of Alimera Sciences Inc (ALIM) are Rs -- and Rs -- as of 08-May-2026.

Alimera Sciences Inc (ALIM) has a market capitalisation of $ 301 Mln as on 18-Sep-2024. As per SEBI classification, it is a Small Cap company.

Before investing in Alimera Sciences Inc (ALIM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.